Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis

The aim of the investigators study was to investigate the safety and efficacy of allogeneic ADSCs for the clinical treatment of knee osteoarthritis.


Eligibility Criteria:
Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Aged 40 to 80 years old (inclusive)
3. Kellgren-Lawrence grading II-IV, as determined by American College ofRheumatology (ACR) criteria for osteoarthritis of the knee
4. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of 7 \~ 17 (inclusive) in the target knee despite use of NSAID
5. Contraindicated to long term systemic NSAID (e.g. suffer from severe gastrointestinal side effects upon systemic NSAID administration, or due to underlying increased gastrointestinal, cardiovascular, or renal risk) and not able to receive or wish to delay knee arthroplasty

Exclusion Criteria:

1. With previous surgery of articular fracture, ligament reconstruction, meniscal reconstruction, and knee arthroplasty on the target knee joint
2. With previous intra-articular intervention (e.g. steroid, anesthetics, hyaluronate, arthroscopic surgery) on the target knee joint 12 weeks prior to screening
3. Administered or required systemic or local on the target knee joint immunosuppressive agent, anti-inflammatory drug, steroid, analgesics, opioid, or duloxetine for OA knee except for acetaminophen and NSAID within 1 week prior to screening
4. With joint diseases other than knee osteoarthritis considered by investigator not eligible to enter the study
5. Unable to receive MRI examination, including allergic to the contrast medium for MRI used in the study, with known history of claustrophobia, having any existing metallic intraocular foreign body or active/inactive implanted medical devices, such as cardiac pacemaker, cochlear, intracranial vascular clips or neurostimulator
6. Active or suspected infection of the target knee joint
7. History of human immunodeficiency virus (HIV) infection
8. History of malignancy within 2 years prior to screening
9. With body mass index (BMI) greater or equal to 35 kg/m2
10. Known hypersensitivity to any component of the investigational product or the active control
11. Participated other investigational study within 4 weeks prior to screening
12. With ongoing or within the past 2 years serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject
13. Female subject with childbearing potential who is lactating or has positive serum or urine pregnancy test at Screening
14. Subject with childbearing potential refuses to use highly effective contraceptives from signing informed consent until Final/Early Termination Visit. At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:

    * Established use of oral, injected or implanted hormonal methods of contraception
    * Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    * Barrier methods of contraception: condom, or occlusive cap (diaphragmor cervical/vault caps)